Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?

AUTOR(ES)

Golan, Yoav

FONTE

BioMed Central

RESUMO

Prior analyses suggest that empiric fluconazole for ICU patients with sepsis is cost-effective. Using updated estimates of efficacy and cost, Zilberberg and colleagues compare the use of micafungin with that of fluconazole. The authors conclude that micafungin is an attractive alternative to fluconazole. This conclusion is driven by recent reduction in micafungin's cost and by better activity of micafungin against azole-resistant Candida species. Their results are limited by inflated estimates of efficacy, life expectancy and risk of Candida sepsis. This commentary explores the rationale for early anti-Candida strategies in the ICU and highlights the contribution and limitations of the article by Zilberberg and colleagues.

Documentos Relacionados

• Detection of serum Candida antigens by enzyme-linked immunosorbent assay and a latex agglutination test with anti-Candida albicans and anti-Candida krusei antibodies.
• Diagnostic value of anti-Candida enolase antibodies.
• Vaginal and Oral Epithelial Cell Anti-Candida Activity
• Immunoglobulin E Anti-Candida Antibodies and Candidiasis †
• Anti-Candida Activity of a New Platinum Derivative